

SYLVESTER INNOVATES

\$1Million Cancer Center Biomedical Competition
\$100K-\$500K Requests



Co-Sponsored by U Innovation



Sylvester Innovates Fund Biomedical Competition

\$1Million Cancer Center Biomedical Competition
\$100K-\$500K Requests

Mission

The Sylvester Innovates Fund (SIF) is designed to accelerate promising translational cancer research projects toward critical value inflection and accretion, catalyzing research commercialization at Sylvester Comprehensive Cancer Center.

Goal

Funded projects are expected to lead to the generation of new intellectual property, technology licensing, and start-up company formation.



Desert Horse Grant
Chief Transformation Officer
Sylvester Comprehensive Cancer
Center

Panelists



Desert Horse Grant
Chief Transformation Officer
Sylvester Comprehensive
Cancer Center



Will Silverman, Ph.D., MBA
Executive Director
Coulter Project



Artavazd Arumov, Ph.D.
Entrepreneur in Residence
University of Miami Miller
School of Medicine



Peter Gutenberg, J.D.
Manager, Intellectual
Property Licensing
Office of Technology Transfer

Tracks

Category	Technology Pilot Funding	Acceleration Funding
Purpose	Support for research to develop a new technology (platform or product)	Support for research with existing IP to generate key pre-clinical data
End Goal	Development of new Intellectual Property (IP)	Increase likelihood of a licensing event (e.g., out-license, NewCo formation)
Project Duration	Up to 1 year	Up to 2 years
Funding Amount	\$100,000 to \$200,000	\$200,000 to \$500,000
Innovation Stage	Early-stage concept or prototype development	Later-stage development with validated or filed IP
Expected Outcome	Creation of new, protectable IP	De-risking the technology to make it more attractive for commercialization



Desert Horse Grant
Chief Transformation Officer
Sylvester Comprehensive Cancer Center

Eligibility

- Principal Investigator (PI, Co-PI) a CCSG Sylvester Full member.
- Categories
 - Therapeutics, Medical Devices, Diagnostics or Digital Health
- For Technology Pilot Funding:
 - No prerequisite requirements for invention disclosure and/or existing IP.
- For Acceleration Funding:
 - An invention disclosure must have been submitted to and favorably reviewed for IP potential by the UM Office of Technology Transfer (OTT) **at least 60 days prior to the application deadline.**
- Grant recipients are invited to submit a follow-on proposal upon the completion of the funded research plan and will be automatically reviewed as finalists during the follow-on grant proposal review.
- Prior to submission, applicants are strongly encouraged to schedule a meeting with the SIF team (sylvesterinnovates@med.miami.edu)



Will Silverman, PhD, MBA
Executive Director
Coulter Project

LOI and Application Template Overview

- LOI
 - Project Choice & Category
 - Narrative (1-3 sentences)
 - Summary (200 words)
 - Technology (200 words)
 - Commercialization Plan (2-3 sentences)
 - Intellectual Property (2 sentences)
- Application
 - Cover Page
 - Background & Significance
 - ✓ Unmet Clinical Need
 - ✓ Standard of Care and Currently Available Solutions
 - ✓ Proposed Solution
 - ✓ Preliminary Results/Research Plan
 - ✓ Intellectual Property & Commercialization
 - Team & Budget



Will Silverman, PhD, MBA
Executive Director
Coulter Project

Industry Review Committee (IRC)



Katie Bodner Spielberg, PhD
Principal 5AM Ventures



Jason Campagna, MD, PhD
CMO Q32 Bio Inc.



Michelle Levine, PhD
Principal Solasta Ventures



J.C. Lopez, MD, MBA
Principal NEA



Angel Martin, PhD
Senior Associate Frazier



Melissa McCracken, PhD
Partner Nextech



George Voren, PhD
VP, Founder Curie.Bio



Kwame Ulmer, MBA, MS
Managing Partner –
MedTech Impact Partners



Artavazd Arumov, PhD
Entrepreneur in Residence
University of Miami Miller
School of Medicine


UM OTT Services

- Intellectual property protection and commercialization
 - Securing protection
 - Marketing
 - Licensing/Agreements
- Material Transfer Agreements (MTA)
 - Outgoing material - OTT
 - Incoming material - ORA
- Confidential Disclosure Agreements (CDA)
 - Outgoing information and mutual CDAs - OTT
 - Incoming information and IICT – ORA
- Intellectual property subject matter experts for all University agreements




Peter Gutenberg, J.D.
Manager, Intellectual
Property Licensing
Office of Technology Transfer

Innovation Disclosure Process



Peter Gutenberg, J.D.
Manager, Intellectual
Property Licensing
Office of Technology Transfer

Important Dates: Application Process & Timeline



Questions?



Nicole Sardina, MBA, MPH
Project Manager, Sylvester
Comprehensive Cancer Center

Contact Information



Desert Horse-Grant

Chief Transformation Officer, Sylvester Comprehensive Cancer Center
dhorsegrant@med.miami.edu



William Silverman PhD, MBA

Executive Director, Coulter Program and New Ventures, University of Miami U Innovation
w.silverman@miami.edu



Artavazd Arumov, PhD

Entrepreneur-in-Residence, University of Miami Miller School of Medicine
aarumov@miami.edu



Whitney Hough, PhD, MBA

Director, Office of Technology Transfer, University of Miami U Innovation
whough@miami.edu



Nicole Sardina, MBA, MPH

Project Manager, Sylvester Comprehensive Cancer Center
nsardina@med.miami.edu



Thank You!